| Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer N Sobhani, A D’Angelo, M Pittacolo, G Roviello, A Miccoli, SP Corona, ... Cells 8 (4), 321, 2019 | 129 | 2019 |
| Methylene blue—current knowledge, fluorescent properties, and its future use T Cwalinski, W Polom, L Marano, G Roviello, A D’Angelo, N Cwalina, ... Journal of clinical medicine 9 (11), 3538, 2020 | 83 | 2020 |
| MSI and EBV positive gastric cancer’s subgroups and their link with novel immunotherapy MG Rodriquenz, G Roviello, A D’Angelo, D Lavacchi, F Roviello, K Polom Journal of clinical medicine 9 (5), 1427, 2020 | 68 | 2020 |
| Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies A D’Angelo, N Sobhani, R Chapman, S Bagby, C Bortoletti, M Traversini, ... Cancers 12 (11), 3293, 2020 | 58 | 2020 |
| Tumor-Agnostic Treatment for Cancer: When How is Better than Where D Lavacchi, G Roviello, A D’Angelo Clinical Drug Investigation, 1-9, 2020 | 42 | 2020 |
| Current status of fibroblast growth factor receptor-targeted therapies in breast cancer N Sobhani, A Ianza, A D’angelo, G Roviello, F Giudici, M Bortul, ... Cells 7 (7), 76, 2018 | 41 | 2018 |
| A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding L Tammaro, A Buda, MC Di Paolo, A Zullo, C Hassan, E Riccio, ... Digestive and Liver Disease 46 (9), 783-787, 2014 | 35 | 2014 |
| Advances in anti-BRAF therapies for lung cancer G Roviello, A D’Angelo, M Sirico, M Pittacolo, FU Conter, N Sobhani Investigational New Drugs 39 (3), 879-890, 2021 | 33 | 2021 |
| Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer G Roviello, A D'Angelo, R Petrioli, F Roviello, F Cianchi, S Nobili, E Mini, ... Translational Oncology 13 (9), 100795, 2020 | 33 | 2020 |
| AR-V7 in metastatic prostate cancer: a strategy beyond redemption N Sobhani, PK Neeli, A D’angelo, M Pittacolo, M Sirico, IC Galli, ... International journal of molecular sciences 22 (11), 5515, 2021 | 30 | 2021 |
| Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma A D’Angelo, N Sobhani, G Roviello, S Bagby, D Bonazza, C Bottin, ... PLoS One 14 (8), e0219566, 2019 | 30 | 2019 |
| Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer N Sobhani, D Generali, A D’Angelo, M Aieta, G Roviello Investigational new drugs 36 (6), 1133-1137, 2018 | 24 | 2018 |
| Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects R Roudi, A D'Angelo, M Sirico, N Sobhani International Immunopharmacology 101, 108322, 2021 | 21 | 2021 |
| Mutant p53 as an antigen in cancer immunotherapy N Sobhani, A D’angelo, X Wang, KH Young, D Generali, Y Li International journal of molecular sciences 21 (11), 4087, 2020 | 20 | 2020 |
| Avelumab in gastric cancer G Roviello, A D’Angelo, D Generali, M Pittacolo, M Ganzinelli, G Iezzi, ... Immunotherapy 11 (9), 759-768, 2019 | 20 | 2019 |
| Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials G Roviello, MR Gatta Michelet, A D’Angelo, S Nobili, E Mini Clinical and Translational Oncology 22, 1033-1039, 2020 | 18 | 2020 |
| TRK fusion positive cancers: from first clinical data of a TRK inhibitor to future directions G Roviello, A D'Angelo, M Sciortino, E Mini, S Nobili, F De Logu, D Massi Critical Reviews in Oncology/Hematology 152, 103011, 2020 | 16 | 2020 |
| Current state and future challenges for PI3K inhibitors in cancer therapy M Sirico, A D’Angelo, C Gianni, C Casadei, F Merloni, U De Giorgi Cancers 15 (3), 703, 2023 | 15 | 2023 |
| Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand A D’Angelo, S Bagby, IC Galli, C Bortoletti, G Roviello Expert Review of Clinical Pharmacology 13 (10), 1139-1146, 2020 | 15 | 2020 |
| Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? G Roviello, G Aprile, A D’Angelo, LF Iannone, F Roviello, K Polom, E Mini, ... Gastric Cancer 24, 765-779, 2021 | 14 | 2021 |
Giandomenico Roviellouniversity of florenceVerified email at unifi.it
